Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2008

View Archived Issues

ViroPharma to acquire Lev under merger agreement

Topical PSD-503 safe and effective for the treatment of stress urinary incontinence

ABT-925 demonstrates regionally selective dopamine D3 occupancy in humans

MGN-1703 begins phase I cancer study

Erbitux approved in Japan for metastatic colorectal cancer

Enrollment progresses in phase II RA study of CH-1504

Provenge studied in localized prostate cancer patients prior to surgery

JN-403, a novel alpha7 nAch receptor profiled at Novartis

Sublingual buprenorphine safe and effective in controlling neonatal abstinence syndrome

Triolex studied in new phase II trial for type 2 diabetes

Recent Dainippon Sumitomo patent describes new analgesic agents

Novel antiinflammatory agents claimed in recent patent literature

Preclinical studies at Karo Bio support the use of ERbeta agonists in treating depression

Sym-001 studied in new phase II trial for ITP

Alzheimer's drug candidate MCD-386 begins phase I trial

Prulifloxacin demonstrates utility in infectious diarrhea

Recent patents disclose new compounds for sleep disorders, anxiety disorders and schizophrenia

Suspension of phase II trial of doxorubicin Transdrug

Japanese approval for Biopten in PKU

Enrollment under way in phase III laquinimod study in RRMS

Enrollment completed in phase I study of Alzheimer's vaccine Affitope AD-01

SPA agreement for LibiGel FSD program in naturally menopausal women

Metabolon expands multistudy agreement with Mitsubishi Tanabe Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...